{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:31:56Z","timestamp":1788870716224,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["N01MH90001"],"award-info":[{"award-number":["N01MH90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH064173"],"award-info":[{"award-number":["R01MH064173"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.schres.2014.01.017","type":"journal-article","created":{"date-parts":[[2014,2,2]],"date-time":"2014-02-02T18:16:12Z","timestamp":1391364972000},"page":"184-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data"],"prefix":"10.1016","volume":"153","author":[{"given":"Kazunari","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Bies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.01.017_bb0005","series-title":"NONMEM User's Guide, Part I","author":"Beal","year":"1992"},{"issue":"12","key":"10.1016\/j.schres.2014.01.017_bb0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.JGP.0000224330.73063.6c","article-title":"Population pharmacokinetics in geriatric psychiatry","volume":"14","author":"Bigos","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.01.017_bb0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2014.01.017_bb0020","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1017\/S0317167100003309","article-title":"Antipsychotic drug-induced movement disorders","volume":"30","author":"Blanchet","year":"2003","journal-title":"Can. J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.schres.2014.01.017_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF00427766","article-title":"Treatment schedule as a determinant of the development of tolerance to haloperidol","volume":"82","author":"Carey","year":"1984","journal-title":"Psychopharmacology (Berl.)"},{"issue":"4","key":"10.1016\/j.schres.2014.01.017_bb0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1996.01830040049009","article-title":"Incidence and correlates of tardive dyskinesia in first episode of schizophrenia","volume":"53","author":"Chakos","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.01.017_bb0035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.01.017_bb0040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4088\/JCP.v65n0305","article-title":"Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol","volume":"65","author":"Dossenbach","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.01.017_bb0045","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/schbul\/23.4.583","article-title":"Treatment of tardive dyskinesia","volume":"23","author":"Egan","year":"1997","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2014.01.017_bb0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.01.017_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002139900333","article-title":"Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels","volume":"149","author":"Fitzgerald","year":"2000","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.schres.2014.01.017_bb0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-0447.107.s416.4.x","article-title":"The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment","volume":"416","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"3","key":"10.1016\/j.schres.2014.01.017_bb0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1034\/j.1600-0447.2003.00064.x","article-title":"The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"issue":"8","key":"10.1016\/j.schres.2014.01.017_bb0075","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4088\/JCP.12m07638","article-title":"A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia","volume":"73","author":"Ikai","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2014.01.017_bb0085","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2014.01.017_bb0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2014.01.017_bb0095","doi-asserted-by":"crossref","first-page":"L103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.schres.2014.01.017_bb0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.01.017_bb0110","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00280-013-2069-1","article-title":"Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3years","volume":"71","author":"Kontny","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.schres.2014.01.017_bb0115","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction","volume":"50","author":"Margolese","year":"2005","journal-title":"Can. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.01.017_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","article-title":"Vancomycin: a review of population pharmacokinetic analyses","volume":"51","author":"Marsot","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.schres.2014.01.017_bb0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2014.01.017_bb0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pnpbp.2011.12.013","article-title":"Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study","volume":"37","author":"Mizuno","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2014.01.017_bb0135","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JCP.0b013e3182979a0a","article-title":"Estimated dopamine D2 receptor occupancy and remission in schizophrenia: analysis of the CATIE data","volume":"33","author":"Moriguchi","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2014.01.017_bb0140","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.v64n0913","article-title":"Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol","volume":"64","author":"Oosthuizen","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.01.017_bb0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/YCO.0b013e328017f6b1","article-title":"Tardive dyskinesia: eliminated, forgotten, or overshadowed?","volume":"20","author":"Remington","year":"2007","journal-title":"Curr. Opin. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2014.01.017_bb0150","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4088\/JCP.09m05866yel","article-title":"\u201cExtended\u201d antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial","volume":"72","author":"Remington","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2014.01.017_bb0160","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"\u201cBreakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2014.01.017_bb0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biopsych.2008.01.010","article-title":"Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery","volume":"64","author":"Samaha","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2014.01.017_bb0165","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data","volume":"5","author":"Sheiner","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"2","key":"10.1016\/j.schres.2014.01.017_bb0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2007-971169","article-title":"Tardive dyskinesia","volume":"27","author":"Soares-Weiser","year":"2007","journal-title":"Semin. Neurol."},{"issue":"1","key":"10.1016\/j.schres.2014.01.017_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2014.01.017_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-12-381328-2.00009-2","article-title":"Epidemiology and risk factors for (tardive) dyskinesia","volume":"98","author":"Tenback","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"issue":"9","key":"10.1016\/j.schres.2014.01.017_bb0190","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4088\/JCP.v66n0907","article-title":"Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study","volume":"66","author":"Tenback","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"16","key":"10.1016\/j.schres.2014.01.017_bb0185","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/mds.22707","article-title":"Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis","volume":"24","author":"Tenback","year":"2009","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.schres.2014.01.017_bb0195","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1176\/ajp.154.9.1248","article-title":"Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.01.017_bb0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","article-title":"The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats","volume":"165","author":"Turrone","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"issue":"4","key":"10.1016\/j.schres.2014.01.017_bb0205","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.biopsych.2004.10.023","article-title":"Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats","volume":"57","author":"Turrone","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.01.017_bb0225","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.2009.133","article-title":"Predicting age-specific dosing of antipsychotics","volume":"86","author":"Uchida","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.schres.2014.01.017_bb0235","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D(2) receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.01.017_bb0220","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FTD.0b013e3182489a6f","article-title":"Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study","volume":"34","author":"Uchida","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"11","key":"10.1016\/j.schres.2014.01.017_bb0245","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0091270010387604","article-title":"Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study","volume":"51","author":"Wessels","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2014.01.017_bb0250","author":"WHO. Collaborating centre for drug statistics methodology"},{"issue":"4","key":"10.1016\/j.schres.2014.01.017_bb0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:25:08Z","timestamp":1760297108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":44,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0920996414000401"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.01.017","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}